System featured prominently this week as it advanced its dual strategy in peptide therapeutics and AI-driven scientific data infrastructure. The privately held company secured $20 million in venture funding to accelerate its push toward becoming a vertically integrated, regulated peptide platform in the U.S. healthcare market.
System aims to control the peptide supply chain end-to-end, pairing patients with U.S.-licensed clinicians who prescribe personalized protocols. These treatments are compounded by certified American pharmacies and shipped directly to consumers, with plans to integrate an in-house compounding pharmacy and move into active pharmaceutical ingredient manufacturing.
The company is emphasizing transparency and regulatory alignment by sourcing exclusively from FDA-registered pharmacies and using third-party lab testing. Its strategy closely tracks recent FDA moves to expand the list of peptides that licensed compounding pharmacies can legally prepare, positioning System to tap into a peptide therapeutics market projected to reach $163 billion by 2026.
In parallel, System is broadening access to its System Public Graph beta ahead of a wider fall launch. The freely available tool maps global scientific knowledge across domains such as health, biology, climate, and economics, and is intended for research and non-commercial use.
The Public Graph has been refined with a limited group of partners and is built on the company’s patented System Graph technology. Expanded beta access suggests continued progress toward validating demand for AI-driven scientific and data knowledge platforms, potentially laying groundwork for future monetization around advanced analytics and infrastructure offerings.
Taken together, this week’s developments underline System’s efforts to build trusted infrastructure in both peptide therapeutics and scientific data, strengthening its position in two rapidly evolving markets and reinforcing its long-term growth prospects.